<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39369233</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1743-422X</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>05</Day></PubDate></JournalIssue><Title>Virology journal</Title><ISOAbbreviation>Virol J</ISOAbbreviation></Journal><ArticleTitle>Oncolytic activity of a coxsackievirus B3 strain in patient-derived cervical squamous cell carcinoma organoids and synergistic effect with paclitaxel.</ArticleTitle><Pagination><StartPage>245</StartPage><MedlinePgn>245</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">245</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12985-024-02502-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Cervical squamous cell carcinoma (CSCC) is a prevalent gynecological malignancy worldwide. Current treatments for CSCC can impact fertility and cause long-term complications, underscoring the need for new therapeutic strategies. Oncolytic virotherapy has emerged as a promising option for cancer treatment. Previous research has demonstrated the oncolytic activity of the coxsackievirus B3 strain 2035 A (CVB3/2035A) against various tumor types. This study aims to evaluate the clinical viability of CVB3/2035A for CSCC treatment, focusing on its oncolytic effect in patient-derived CSCC organoids.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The oncolytic effects of CVB3/2035A were investigated using human CSCC cell lines in vitro and mouse xenograft models in vivo. Preliminary tests for tumor-selectivity were conducted on patient-derived CSCC tissue samples and compared to normal cervical tissues ex vivo. Three patient-derived CSCC organoid lines were developed and treated with CVB3/2035A alone and in combination with paclitaxel. Both cytotoxicity and virus replication were evaluated in vitro.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">CVB3/2035A exhibited significant cytotoxic effects in human CSCC cell lines and xenograft mouse models. The virus selectively induced oncolysis in patient-derived CSCC tissue samples while sparing normal cervical tissues ex vivo. In patient-derived CSCC organoids, which retained the immunohistological characteristics of the original tumors, CVB3/2035A also demonstrated significant cytotoxic effects and efficient replication, as evidenced by increased viral titers and presence of viral nucleic acids and proteins. Notably, the combination of CVB3/2035A and paclitaxel resulted in enhanced cytotoxicity and viral replication.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">CVB3/2035A showed oncolytic activity in CSCC cell lines, xenografts, and patient-derived tissue cultures and organoids. Furthermore, the virus exhibited synergistic anti-tumor effects with paclitaxel against CSCC. These results suggest CVB3/2035A could serve as an alternative or adjunct to current CSCC chemotherapy regimens.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lin</LastName><ForeName>Yanzhen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongshan Hospital, Xiamen University, Xiamen, 361004, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Liu</LastName><ForeName>Nanyi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Chuanlai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Haoyin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Changjian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Kang</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Huan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xia</LastName><ForeName>Ningshao</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Wei</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China. lukewang@xmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China. lukewang@xmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Xiumin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Obstetrics and Gynecology, Zhongshan Hospital, Xiamen University, Xiamen, 361004, China. huangxmxm@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheng</LastName><ForeName>Tong</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Vaccines for Infectious Diseases, Xiang An Biomedicine Laboratory, School of Life Sciences, School of Public Health, Xiamen University, Xiamen, 361102, China. tcheng@xmu.edu.cn.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institute of Diagnostics and Vaccine Development in Infectious Diseases, National Innovation Platform for Industry-Education Integration in Vaccine Research, Xiamen University, Xiamen, 361102, China. tcheng@xmu.edu.cn.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2022J011352</GrantID><Agency>Natural Science Foundation of Fujian Province of China</Agency><Country /></Grant><Grant><GrantID>82272310</GrantID><Agency>National Natural Science Foundation of China</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Virol J</MedlineTA><NlmUniqueID>101231645</NlmUniqueID><ISSNLinking>1743-422X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="Y">Paclitaxel</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002583" MajorTopicYN="Y">Uterine Cervical Neoplasms</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009940" MajorTopicYN="Y">Organoids</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="Y">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050130" MajorTopicYN="Y">Oncolytic Virotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002294" MajorTopicYN="Y">Carcinoma, Squamous Cell</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D050504" MajorTopicYN="Y">Oncolytic Viruses</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D023041" MajorTopicYN="Y">Xenograft Model Antitumor Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="N">Virus Replication</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cervical squamous cell carcinoma</Keyword><Keyword MajorTopicYN="N">Coxsackievirus B3</Keyword><Keyword MajorTopicYN="N">Oncolytic virus</Keyword><Keyword MajorTopicYN="N">Organoid</Keyword><Keyword MajorTopicYN="N">Virotherapy</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>13</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>6</Day><Hour>13</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>5</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39369233</ArticleId><ArticleId IdType="pmc">PMC11452971</ArticleId><ArticleId IdType="doi">10.1186/s12985-024-02502-y</ArticleId><ArticleId IdType="pii">10.1186/s12985-024-02502-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.</Citation><ArticleIdList><ArticleId IdType="pubmed">33538338</ArticleId></ArticleIdList></Reference><Reference><Citation>Lõhmussaar K, Oka R, Espejo Valle-Inclan J, Smits MHH, Wardak H, Korving J, et al. Patient-derived organoids model cervical tissue dynamics and viral oncogenesis in cervical cancer. Cell Stem Cell. 2021;28(8):1380–e966.</Citation><ArticleIdList><ArticleId IdType="pubmed">33852917</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen PA, Jhingran A, Oaknin A, Denny L. Cervical cancer. Lancet. 2019;393(10167):169–82.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638582</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D, Shen Y, Liang T. Oncolytic virotherapy: basic principles, recent advances and future directions. Signal Transduct Target Ther. 2023;8(1):156.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10090134</ArticleId><ArticleId IdType="pubmed">37041165</ArticleId></ArticleIdList></Reference><Reference><Citation>Shalhout SZ, Miller DM, Emerick KS, Kaufman HL. Therapy with oncolytic viruses: progress and challenges. Nat Rev Clin Oncol. 2023;20(3):160–77.</Citation><ArticleIdList><ArticleId IdType="pubmed">36631681</ArticleId></ArticleIdList></Reference><Reference><Citation>Geisler A, Hazini A, Heimann L, Kurreck J, Fechner H. Coxsackievirus B3-Its potential as an Oncolytic Virus. Viruses. 2021;13(5).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8143167</ArticleId><ArticleId IdType="pubmed">33919076</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Wang W, Wan J, Yang Y, Fu W, Pan D, et al. Oncolytic activity of a coxsackievirus B3 strain in human endometrial cancer cell lines. Virol J. 2018;15(1):65.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5891967</ArticleId><ArticleId IdType="pubmed">29631630</ArticleId></ArticleIdList></Reference><Reference><Citation>Reeh M, Bockhorn M, Görgens D, Vieth M, Hoffmann T, Simon R, et al. Presence of the Coxsackievirus and Adenovirus receptor (CAR) in human neoplasms: a multitumour array analysis. Br J Cancer. 2013;109(7):1848–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3790165</ArticleId><ArticleId IdType="pubmed">24022195</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Wu M, Huang A, Gao C, Yang Y, Liu H et al. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient’s response to conventional and novel therapies. J Translational Med. 2023;21(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10492358</ArticleId><ArticleId IdType="pubmed">37689699</ArticleId></ArticleIdList></Reference><Reference><Citation>Bleijs M, van de Wetering M, Clevers H, Drost J. Xenograft and organoid model systems in cancer research. EMBO J. 2019;38(15).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6670015</ArticleId><ArticleId IdType="pubmed">31282586</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann C, Bachran C, Stanke J, Elezkurtaj S, Kaufmann AM, Fuchs H, et al. Creation and characterization of a xenograft model for human cervical cancer. Gynecol Oncol. 2010;118(1):76–80.</Citation><ArticleIdList><ArticleId IdType="pubmed">20441999</ArticleId></ArticleIdList></Reference><Reference><Citation>Veninga V, Voest EE. Tumor organoids: opportunities and challenges to guide precision medicine. Cancer Cell. 2021;39(9):1190–201.</Citation><ArticleIdList><ArticleId IdType="pubmed">34416168</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6112415</ArticleId><ArticleId IdType="pubmed">29472484</ArticleId></ArticleIdList></Reference><Reference><Citation>Sachs N, de Ligt J, Kopper O, Gogola E, Bounova G, Weeber F et al. A living biobank of breast Cancer Organoids captures Disease Heterogeneity. Cell. 2018;172(1–2):373 – 86 e10.</Citation><ArticleIdList><ArticleId IdType="pubmed">29224780</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill SJ, Decker B, Roberts EA, Horowitz NS, Muto MG, Worley MJ Jr., et al. Prediction of DNA repair inhibitor response in short-term patient-derived ovarian Cancer Organoids. Cancer Discov. 2018;8(11):1404–21.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6365285</ArticleId><ArticleId IdType="pubmed">30213835</ArticleId></ArticleIdList></Reference><Reference><Citation>Puca L, Bareja R, Prandi D, Shaw R, Benelli M, Karthaus WR, et al. Patient derived organoids to model rare prostate cancer phenotypes. Nat Commun. 2018;9(1):2404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6008438</ArticleId><ArticleId IdType="pubmed">29921838</ArticleId></ArticleIdList></Reference><Reference><Citation>Ingemarsdotter CK, Baird SK, Connell CM, Oberg D, Hallden G, McNeish IA. Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene. 2010;29(45):6051–63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3007619</ArticleId><ArticleId IdType="pubmed">20729921</ArticleId></ArticleIdList></Reference><Reference><Citation>Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, et al. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 2021;184(18):4753–e7127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8557351</ArticleId><ArticleId IdType="pubmed">34388391</ArticleId></ArticleIdList></Reference><Reference><Citation>Jun E, Park Y, Lee W, Kwon J, Lee S, Kim MB et al. The identification of candidate effective combination regimens for pancreatic cancer using the histoculture drug response assay. Sci Rep. 2020;10(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7371642</ArticleId><ArticleId IdType="pubmed">32686712</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopper O, de Witte CJ, Lohmussaar K, Valle-Inclan JE, Hami N, Kester L, et al. An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity. Nat Med. 2019;25(5):838–49.</Citation><ArticleIdList><ArticleId IdType="pubmed">31011202</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Xu H, Gong Y, Chen W, Zhan Y, Yu L et al. Patient-derived Upper Tract Urothelial Carcinoma Organoids as a platform for drug screening. Adv Sci. 2021;9(4).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8811809</ArticleId><ArticleId IdType="pubmed">34914855</ArticleId></ArticleIdList></Reference><Reference><Citation>Bourgeois-Daigneault MC, St-Germain LE, Roy DG, Pelin A, Aitken AS, Arulanandam R, et al. Combination of Paclitaxel and MG1 oncolytic virus as a successful strategy for breast cancer treatment. Breast Cancer Res. 2016;18(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4977613</ArticleId><ArticleId IdType="pubmed">27503504</ArticleId></ArticleIdList></Reference><Reference><Citation>Annels NE, Arif M, Simpson GR, Denyer M, Moller-Levet C, Mansfield D, et al. Oncolytic immunotherapy for bladder Cancer using Coxsackie A21 Virus. Mol Ther Oncolytics. 2018;9:1–12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035483</ArticleId><ArticleId IdType="pubmed">29989024</ArticleId></ArticleIdList></Reference><Reference><Citation>Annels NE, Mansfield D, Arif M, Ballesteros-Merino C, Simpson GR, Denyer M, et al. Phase I trial of an ICAM-1-Targeted immunotherapeutic-Coxsackievirus A21 (CVA21) as an Oncolytic Agent Against non muscle-invasive bladder Cancer. Clin Cancer Res. 2019;25(19):5818–31.</Citation><ArticleIdList><ArticleId IdType="pubmed">31273010</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyamoto S, Inoue H, Nakamura T, Yamada M, Sakamoto C, Urata Y, et al. Coxsackievirus B3 is an oncolytic virus with immunostimulatory properties that is active against lung adenocarcinoma. Cancer Res. 2012;72(10):2609–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">22461509</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng H, Liu H, de Silva T, Xue Y, Mohamud Y, Ng CS, et al. Coxsackievirus Type B3 is a potent oncolytic virus against KRAS-Mutant Lung Adenocarcinoma. Mol Therapy - Oncolytics. 2019;14:266–78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6709373</ArticleId><ArticleId IdType="pubmed">31463367</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahreyni A, Mohamud Y, Ashraf Nouhegar S, Zhang J, Luo H. Synergistic viro-chemoimmunotherapy in breast Cancer enabled by Bioengineered Immunostimulatory exosomes and Dual-targeted Coxsackievirus B3. ACS Nano. 2024;18(5):4241–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10851665</ArticleId><ArticleId IdType="pubmed">38278522</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazini A, Pryshliak M, Bruckner V, Klingel K, Sauter M, Pinkert S, et al. Heparan Sulfate binding Coxsackievirus B3 strain PD: a Novel Avirulent Oncolytic Agent Against Human Colorectal Carcinoma. Hum Gene Ther. 2018;29(11):1301–14.</Citation><ArticleIdList><ArticleId IdType="pubmed">29739251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalafati E, Drakopoulou E, Anagnou NP, Pappa KI. Developing oncolytic viruses for the treatment of Cervical Cancer. Cells. 2023;12(14).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10377776</ArticleId><ArticleId IdType="pubmed">37508503</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan HHN, Chan AS, Lai FP, Leung SY. Organoid cultures for cancer modeling. Cell Stem Cell. 2023;30(7):917–37.</Citation><ArticleIdList><ArticleId IdType="pubmed">37315564</ArticleId></ArticleIdList></Reference><Reference><Citation>Raimondi G, Mato-Berciano A, Pascual-Sabater S, Rovira-Rigau M, Cuatrecasas M, Fondevila C, et al. Patient-derived pancreatic tumour organoids identify therapeutic responses to oncolytic adenoviruses. EBioMedicine. 2020;56:102786.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7251378</ArticleId><ArticleId IdType="pubmed">32460166</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida GJ. Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol. 2020;13(1).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6947974</ArticleId><ArticleId IdType="pubmed">31910904</ArticleId></ArticleIdList></Reference><Reference><Citation>Soliman H, Hogue D, Han H, Mooney B, Costa R, Lee MC, et al. Oncolytic T-VEC virotherapy plus neoadjuvant chemotherapy in nonmetastatic triple-negative breast cancer: a phase 2 trial. Nat Med. 2023;29(2):450–7.</Citation><ArticleIdList><ArticleId IdType="pubmed">36759673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin SF, Gao SP, Price DL, Li S, Chou TC, Singh P, et al. Synergy of a herpes oncolytic virus and paclitaxel for anaplastic thyroid cancer. Clin Cancer Res. 2008;14(5):1519–28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2719715</ArticleId><ArticleId IdType="pubmed">18316577</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng X, Shen Y, Yi M, Zhang C, Zhao B, Zhong G et al. Combination of novel oncolytic herpesvirus with paclitaxel as an efficient strategy for breast cancer therapy. J Med Virol. 2023;95(5).</Citation><ArticleIdList><ArticleId IdType="pubmed">37212336</ArticleId></ArticleIdList></Reference><Reference><Citation>Shinoda S, Sharma NS, Nakamura N, Inoko K, Sato-Dahlman M, Murugan P, et al. Interferon‐expressing oncolytic adenovirus + chemoradiation inhibited pancreatic cancer growth in a hamster model. Cancer Sci. 2023;114(9):3759–69.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10475772</ArticleId><ArticleId IdType="pubmed">37439437</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Luo H. Development of Group B Coxsackievirus as an Oncolytic Virus: opportunities and challenges. Viruses. 2021;13(6).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8227215</ArticleId><ArticleId IdType="pubmed">34198859</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia Y, Miyamoto S, Soda Y, Takishima Y, Sagara M, Liao J, et al. Extremely low Organ toxicity and strong antitumor activity of mir-34-Regulated Oncolytic Coxsackievirus B3. Mol Ther Oncolytics. 2019;12:246–58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6406029</ArticleId><ArticleId IdType="pubmed">30891489</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauntt CJ, Trousdale MD, LaBadie DR, Paque RE, Nealon T. Properties of coxsackievirus B3 variants which are amyocarditic or myocarditic for mice. J Med Virol. 1979;3(3):207–20.</Citation><ArticleIdList><ArticleId IdType="pubmed">225441</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CK, Kono K, Haas E, Kim KS, Drescher KM, Chapman NM, et al. Characterization of an infectious cDNA copy of the genome of a naturally occurring, avirulent coxsackievirus B3 clinical isolate. J Gen Virol. 2005;86(Pt 1):197–210.</Citation><ArticleIdList><ArticleId IdType="pubmed">15604447</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu H, Xue YC, Deng H, Mohamud Y, Ng CS, Chu A, et al. MicroRNA modification of Coxsackievirus B3 decreases its toxicity, while retaining Oncolytic Potency against Lung Cancer. Mol Ther Oncolytics. 2020;16:207–18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7036525</ArticleId><ArticleId IdType="pubmed">32123721</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahreyni A, Liu H, Mohamud Y, Xue YC, Zhang J, Luo H. A new miRNA-Modified coxsackievirus B3 inhibits triple negative breast cancer growth with improved safety profile in immunocompetent mice. Cancer Lett. 2022;548:215849.</Citation><ArticleIdList><ArticleId IdType="pubmed">35995138</ArticleId></ArticleIdList></Reference><Reference><Citation>Sagara M, Miyamoto S, Itoh S, Soda Y, Tani K. Development of New Oncolytic Virotherapy targeting breast Cancer using Coxsackievirus B3. Anticancer Res. 2021;41(1):81–9.</Citation><ArticleIdList><ArticleId IdType="pubmed">33419801</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>